苯磺酸铵 | 19402-64-3

• 物质功能分类: 化学试剂 - 有机试剂 - 磺酸盐/亚磺酸盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苯磺酸铵
• 英文名称: ammonium benzenesulfonate
• 英文别名: benzenesulfonic acid ; ammonium salt；Benzolsulfonsaeure; Ammonium-Salz；Benzolsulfonsaeure; Ammonium-Verbindung；Ammonium benzenesulphonate；benzenesulfonic acid ammonium；Benzenesulfonic acid, ammonium salt；azanium;benzenesulfonate
• CAS: 19402-64-3
• 化学式: C₆H₆O₃S*H₃N
• 分子量: 175.208
• InChiKey: WWLOCCUNZXBJFR-UHFFFAOYSA-N

物化性质

• 熔点：
  284-285 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存于室温下，密封保存，并确保环境干燥。

反应信息

• 作为反应物：
  描述：

  苯磺酸铵 、 2-硝基苯甲腈 生成 2-nitrobenzamidine
  参考文献：
  名称：

  Effect of theory-based feature correlations on typicality judgments

  摘要：

  In the present study, we examine what types of feature correlations are salient in our conceptual representations. It was hypothesized that of all possible feature pairs, those that are explicitly recognized as correlated (i.e., explicit pairs) and affect typicality judgments are the ones that are more likely theory based than are those that are not explicitly recognized (i.e., implicit pairs). Real-world categories and their properties, taken from Malt and Smith (1984), were examined. We found that explicit pairs had a greater number of asymmetric dependency relations (i.e., one feature depends on the other feature, but not vice versa) and stronger dependency relations than did implicit pairs, which were statistically correlated in the environment but were not recognized as such. In addition, people more often provided specific relation labels for explicit pairs than for implicit pairs; these labels were most often causal relations. Finally, typicality judgments were more affected when explicit correlations were broken than when implicit correlations were broken. It is concluded that in natural categories, feature correlations that are explicitly represented and affect typicality judgments are the ones about which people have theories.

  DOI：

  10.3758/bf03195270
• 作为产物：
  描述：

  苯磺酰氯 在 氨 作用下， 以 氯仿 为溶剂， 生成 苯磺酸铵
  参考文献：
  名称：

  Hamed, A. A.; El-Bieh, A. A.; Baddawy, H. A., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1980, vol. 19, # 3, p. 221 - 223

  摘要：

  DOI：
• 作为试剂：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 苯磺酸铵 作用下， 生成 2-萘羧酰胺
  参考文献：
  名称：

  Effect of theory-based feature correlations on typicality judgments

  摘要：

  In the present study, we examine what types of feature correlations are salient in our conceptual representations. It was hypothesized that of all possible feature pairs, those that are explicitly recognized as correlated (i.e., explicit pairs) and affect typicality judgments are the ones that are more likely theory based than are those that are not explicitly recognized (i.e., implicit pairs). Real-world categories and their properties, taken from Malt and Smith (1984), were examined. We found that explicit pairs had a greater number of asymmetric dependency relations (i.e., one feature depends on the other feature, but not vice versa) and stronger dependency relations than did implicit pairs, which were statistically correlated in the environment but were not recognized as such. In addition, people more often provided specific relation labels for explicit pairs than for implicit pairs; these labels were most often causal relations. Finally, typicality judgments were more affected when explicit correlations were broken than when implicit correlations were broken. It is concluded that in natural categories, feature correlations that are explicitly represented and affect typicality judgments are the ones about which people have theories.

  DOI：

  10.3758/bf03195270

文献信息

• Anti-Pneumocystis carinii pneumonia activity of dicationic 2,4-diarylpyrimidines
  作者：A Kumar、DW Boykin、WD Wilson、SK Jones、BK Bender、CC Dykstra、JE Hall、RR Tidwell

  DOI：10.1016/0223-5234(96)83970-5

  日期：1996.1

  A synthesis of 2,4-bis-(4-amidinophenyl)pyrimidine 6, 2,4-bis-[(4-imidazolin-2-yl)phenyl)]pyrimidine 7, 2,4-bis [(4-tetrahydropyrimidinyl-2-yl)phenyl]pyrimidine 8, 2,4-bis[(4-N-n-propylamidino)phenyl]pyrimidine 9, 2,4-bis[(4-N-isopropylamidino)-phenyl]pyrimidine 10 and 2,4-bis[(4-N-isobutylamidino)phenyl]pyrimidine 11 starting from 4-bromobenzamidine and 4-bromoaceto-phenone is reported. A synthesis

  2,4-双-(4-脒基苯基)嘧啶 6, 2,4-双-[(4-咪唑啉-2-基)苯基)]嘧啶 7, 2,4-双 [(4-四氢嘧啶基- 2-基)苯基]嘧啶 8, 2,4-双[(4-N-丙基脒基)苯基]嘧啶 9, 2,4-双[(4-N-异丙基脒基)-苯基]嘧啶 10 和 2,4-据报道，双[(4-N-异丁基脒基)苯基]嘧啶 11 从 4-溴苯甲脒和 4-溴苯乙酮开始。合成 2-(4-amidinopnenyl)-4-(2-methoxy-4-amidinophenyl)pyrimidine 20, 2-[4-(imidazolin2-yl)-phenyl]-4-[2-me thoxy-4-(咪唑啉-2-基)苯基]嘧啶 21，和 2-[4-(N-异丙基脒基)苯基]-4-[2-甲氧基-4-(N-异丙基)苯基]嘧啶 22描述了 4-溴苯甲脒和 2-甲氧基-4-溴苯乙酮。化合物 6-11 和 20-22 都与
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：CHIESI FARMA SPA

  公开号：WO2014095700A1

  公开（公告）日：2014-06-26

  This invention relates to heterocyclic compounds, which are pyrimidinone derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.

  这项发明涉及杂环化合物，这些化合物是吡咯啉酮衍生物，具有人类中性粒细胞弹性蛋白酶抑制性能，并且它们在治疗中的应用。
• BENZYLPIPERIZINE COMPOUND
  申请人：Toyoda Tomohiro

  公开号：US20100113792A1

  公开（公告）日：2010-05-06

  Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R 1 represents a hydrogen atom or a methyl group; R 2 is a group bound in a p- or m-position relative to a methylene group and represents a chlorine atom bound in a p-position, a bromine atom bound in a p-position, a methyl group bound in a p-position, a chlorine atom bound in a m-position or a bromine atom bound to in a m-position; X represents a methylene or an oxygen atom; and n represents an integer of 1 to 3.)

  揭示了一种由化学式（1）表示的苄基哌嗪化合物或其药学上可接受的盐，该化合物可用作药用剂，如抗抑郁剂。（在化学式（1）中，R1代表氢原子或甲基基团；R2是与亚甲基基团相对的p-或m-位置上结合的基团，代表结合在p-位置的氯原子、结合在p-位置的溴原子、结合在p-位置的甲基基团、结合在m-位置的氯原子或结合在m-位置的溴原子；X代表亚甲基或氧原子；n代表1到3的整数。）
• SUBSTITUTED PYRIMIDINES
  申请人：Gant Thomas G.

  公开号：US20080242687A1

  公开（公告）日：2008-10-02

  Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本文披露了一种Formula I的取代嘧啶基内皮素调节剂，其制备方法、药物组合物以及使用方法。
• [EN] TWO CRYSTALLINE HYDRATE FORMS OF AMLODIPINE BENZENESULFONATE OF HIGH PURITY, PROCESSES FOR THEIR PREPARATION AND USE<br/>[FR] DEUX FORMES DIHYDRATE CRISTALLIN DE BENZENESULFONATE D'AMLODIPINE A PURETE ELEVEE, LEURS PROCEDES DE PREPARATION ET LEUR UTILISATION
  申请人：LEK PHARMACEUTICALS

  公开号：WO2003101965A1

  公开（公告）日：2003-12-11

  The novel crystalline amlodipine benzenesulfonate dihydrate of high purity is disclosed, as well as the process for preparation of the novel crystalline amlodipine benzenesulfonate dihydrate of high purity and the crystalline amlodipine benzenesulfonate monohydrate of high purity, suitable for the preparation of pharmaceutical formulations for the treatment of cardiac diseases or hypertension, and their use as intermediate compounds in the improved process of purification of the nonhydrate benzenesulfonate (besylate) salt of amlodipine.The process for preparation of the crystalline amlodipine benzenesulfonate dihydrate is carried in the way that from the C1-C5 alcoholic solution of amlodipine benzenesulfonate with water while stirring at a temperature of 20°C or lower the crystals of pure amlodipine benzenesulfonate dihydrate are separated, and isolated.The process for preparation of the crystalline amlodipine benzenesulfonate monohydrate is carried in the way that from the C1-C5 alcoholic solution of amlodipine benzenesulfonate with water while stirring at a temperature of 30°C or higher the crystals of pure amlodipine benzenesulfonate monohydrate are separated, and isolated.

  揭示了高纯度的新型结晶氨氯地平苯磺酸苄水合物，以及制备高纯度的新型结晶氨氯地平苯磺酸苄水合物和高纯度的结晶氨氯地平苯磺酸苄单水合物的过程，适用于制备用于治疗心脏疾病或高血压的药物配方，并将它们用作改进的非水合物苯磺酸苄酯盐（besylate）的氨氯地平纯化过程中的中间化合物。制备结晶氨氯地平苯磺酸苄水合物的过程是这样进行的：在20°C或更低温度下，从氨氯地平苯磺酸苄的C1-C5醇溶液中加入水搅拌，分离并提取出纯净的氨氯地平苯磺酸苄水合物晶体。制备结晶氨氯地平苯磺酸苄单水合物的过程是这样进行的：在30°C或更高温度下，从氨氯地平苯磺酸苄的C1-C5醇溶液中加入水搅拌，分离并提取出纯净的氨氯地平苯磺酸苄单水合物晶体。